GAITHERSBURG, Md., Sept. 28, 2016 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced that Douglas E. Brough, Ph.D., the company's chief scientific officer, will present "Exploring the AdenoVerse™ Platform for New Advanced Cell and Gene Therapies", a brief review of GenVec's technology platform, at the 2016 Cell & Gene Meeting on the Mesa (CGMOM). This presentation will highlight new data that demonstrate the utility of select AdenoVerse vectors for efficient gene delivery to immune system cells, including T cells. GenVec believes that these vectors can be applied for therapeutic approaches focusing on genetically modified human primary T cells. GenVec has extensive expertise translating innovative product concepts from the laboratory to the clinic. The company's proprietary vectors are particularly well suited for the delivery of large therapeutic gene payloads, including gene editing technologies, for a wide a variety of treatment strategies.
Dr. Brough's presentation is scheduled for Wednesday, October 5, beginning at 11 a.m. PDT/2:00 p.m. EDT. A live video webcast of all company presentations at the CGMOM will be available at: www.meetingonthemesa.com/webcast during the proceedings; and the slides from Dr. Brough's presentation will be posted for review at www.genvec.com in the Media section, presentations collection. GenVec will post a video replay of Dr. Brough's talk on the company website at the same location when the video clip becomes available after the meeting concludes.
GenVec is a clinical-stage gene delivery company focused on developing a pipeline of cutting-edge therapeutics and vaccines using its proprietary AdenoVerse platform. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to its internal and partnered pipeline, the company is also focused on opportunities to license its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
Statements herein relating to future business performance, conditions or strategies and other financial and business matters, including with respect to expansion of the reach of GenVec's technology platform, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. The forward-looking statements speak only as of the date of this presentation, and GenVec assumes no duty to update forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genvec-to-present-at-2016-cell--gene-meeting-on-the-mesa-300335436.html
SOURCE GenVec, Inc.